Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...

The FDA acknowledged that it has received reports that some patients and pharmacists are not able to obtain the semaglutide injection products through the normal supply chain. However, the FDA ...

KEY TAKEAWAYS Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss ...

Kristie Reed, PharmD, oversees emergency, general medical, surgical, psychiatric care, and oncology medication as the pharmacy director of a community hospital. Dr. Reed specializes in IV medications.

Novo Nordisk announced updates to the Wegovy® savings program, allowing all eligible cash-paying patients access to Wegovy® ...

Wegovy is also available through NovoCare Pharmacy, which directly ship all dose strengths at a cost of $499 per month for ...

Launched in 2015, Trulicity is making an impact in the competitive GLP-1 market, much of its appeal derived from it more convenient weekly injection ... and safety of 0.5 mg semaglutide compared ...

The use of semaglutide in patients with diabetes was associated with a significantly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION) compared with those taking drugs for ...

Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...

The global weight-loss drug market is expected to reach $150 billion in the next decade. By 2026, semaglutide (the active ...